Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on
endothelial function and autonomic nervous system in hypertensive patients with
ischemic heart disease.
Author(s): Ozeki A(1), Amiya E, Watanabe M, Hosoya Y, Takata M, Watanabe A, Kawarasaki S,
Nakao T, Watanabe S, Omori K, Yamada N, Tahara Y, Hirata Y, Nagai R.
Affiliation(s): Author information:
(1)Department of Cardiovascular Medicine, Graduate School of Medicine, the
University of Tokyo, Tokyo, Japan.
Publication date & source: 2014, J Clin Hypertens (Greenwich). , 16(8):591-8
The aim of this study was to evaluate the add-on effect of aliskiren to valsartan
on endothelial-dependent vasodilation in hypertensive patients with ischemic
heart disease (IHD). After 4 weeks of treatment with 80 mg of valsartan, 28
patients were allocated to either continued treatment with valsartan or an add-on
treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly
decreased plasma renin activity, whereas endothelium-dependent vasodilation
measured by flow-mediated dilation (FMD) did not change. In contrast, heart rate
significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline
and 24 weeks, respectively [P = .009]) and the standard deviation of the R-R
intervals (SDNN) significantly increased in the aliskiren group. The add-on
aliskiren to valsartan therapy may not improve endothelial functions, although it
significantly reduced resting heart rate via regulation of the autonomic nervous
system in hypertensive patients with IHD.
|